A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head

• Published in: International orthopaedics 2016-08, Vol.40 (8), p.1747-1754
• Main Authors: Kuroda, Yutaka, Asada, Ryuta, So, Kazutaka, Yonezawa, Atsushi, Nankaku, Manabu, Mukai, Kumi, Ito-Ihara, Toshiko, Tada, Harue, Yamamoto, Michio, Murayama, Toshinori, Morita, Satoshi, Tabata, Yasuhiko, Yokode, Masayuki, Shimizu, Akira, Matsuda, Shuichi, Akiyama, Haruhiko
• Format: Article
• Language: English
• Subjects: Adult; Delayed-Action Preparations; Female; Femur Head - surgery; Femur Head Necrosis - surgery; Fibroblast Growth Factor 2 - chemistry; Fibroblast Growth Factor 2 - metabolism; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Original Paper; Orthopedics; Pilot Projects; Radiography; Recombinant Proteins - chemistry; Recombinant Proteins - metabolism; Regeneration - genetics; Regeneration - physiology; Tomography, X-Ray Computed
• ISSN: 0341-2695; 1432-5195
• DOI: 10.1007/s00264-015-3083-1

Purpose We evaluated the safety and clinical outcomes of a single local administration of gelatin hydrogel impregnated with recombinant human fibroblast growth factor (rhFGF)-2 for the treatment of the precollapse stage of osteonecrosis of the femoral head (ONFH). Methods Patients with ONFH (precollapse stage ≤2) received a single local administration of 800 μg of rhFGF-2-impregnated gelatin hydrogel and were followed up for one year. The surgery was performed using a minimally invasive technique involving a 1-cm skin incision, and walking was allowed from day one postoperatively. The primary outcomes included occurrence of adverse events and complications. The secondary outcomes included changes in the Harris hip scores, visual analog scale for pain scores, University of California, Los Angeles (UCLA) activity scores, and radiological images. Results We included ten patients, of which five experienced 14 adverse events, including one complication from spinal anesthesia. However, patients completely recovered from all adverse events. The mean clinical scores significantly improved by one year postoperatively compared with the pre-operative scores (before vs. after: visual analog score for pain, 21.2 vs. 5.3 mm; UCLA activity score, 5.5 vs. 6.6; Harris hip score, 81.0 vs. 96.9 points). There was only one case of femoral head collapse; however, this occurred in a hip with extensive necrosis. Stage progression and collapse did not occur in the other nine cases. Computed tomography confirmed bone regeneration in the femoral heads. Conclusions Clinical application of rhFGF-2-impregnated gelatin hydrogel for patients with precollapse ONFH was feasible and safe.